Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E5YG
|
|||
| Former ID |
DCL000454
|
|||
| Drug Name |
AZD1236
|
|||
| Synonyms |
(S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; 459814-90-5; AZD1236; AZD-1236; UNII-B4OQY51WZS; B4OQY51WZS; (S)-5-(((4-((5-Chloropyridin-2-yl)oxy)piperidin-1-yl)-sulfonyl)methyl)-5-methylimidazolidine-2,4-dione; SCHEMBL942315; GTPL7844; DTXSID30647184; SFJFBTPHDHUUPU-OAHLLOKOSA-N; AZD 1236; 6326AB; ZINC59688588; AKOS016011525; DB11961; AX8246058; KB-211575; AJ-113592; Piperidine, 4-((5-chloro-2-pyridinyl)oxy)-1-((((4S)-4-methyl-2,5-dioxo-4-imidazolidinyl)methyl)sulfonyl)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 2 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H19ClN4O5S
|
|||
| Canonical SMILES |
CC1(C(=O)NC(=O)N1)CS(=O)(=O)N2CCC(CC2)OC3=NC=C(C=C3)Cl
|
|||
| InChI |
1S/C15H19ClN4O5S/c1-15(13(21)18-14(22)19-15)9-26(23,24)20-6-4-11(5-7-20)25-12-3-2-10(16)8-17-12/h2-3,8,11H,4-7,9H2,1H3,(H2,18,19,21,22)/t15-/m1/s1
|
|||
| InChIKey |
SFJFBTPHDHUUPU-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 459814-89-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Matrix metalloproteinase-12 (MMP-12) | Target Info | Inhibitor | [3] |
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| WikiPathways | TGF beta Signaling Pathway | |||
| Degradation of collagen | ||||
| Matrix Metalloproteinases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7844). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026714) | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.